Most ­surveillance ­recommendations for Li-Fraumeni patients and their families focus mainly on breast and colorectal cancer surveillance, which may be insufficient given the high-risk for other types of cancer such as bone and soft tissue sarcoma (diagnosed in 25% of all germline TP53 MC [48]), brain tumours, leukaemia, adrenocortical carcinoma among others less frequently observed (gastric, prostate, pancreas, melanoma, lymphoma) [45, 47, 49–51]. The gene discussed is TP53; the disease is colorectal cancer.